Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Coya Therapeutics, Inc. (COYA) reports that the 100th patient has been enrolled in its ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, a combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (ALS).
The company plans to enroll approximately 120 participants, randomized 1:1:1 to two COYA 302 dosing regimens or placebo over a 24-week double-blind phase, followed by a 24-week blinded active-treatment extension, providing up to 48 weeks of COYA 302 data. Based on current trends, Coya anticipates completing enrollment in time to report topline data in early Q2 2027. The primary endpoint is change in disease severity from baseline to Week 24 using ALSFRS-R, with additional objectives including efficacy, safety, tolerability, biological activity and biomarker levels.
Coya Therapeutics, Inc., a clinical-stage biotech focused on regulatory T cell–based therapies, reported continued operating losses while maintaining a solid cash position for the quarter ended June 30, 2026. Cash and cash equivalents were $43.2 million, with total assets of $47.3 million and total liabilities of $4.0 million, leaving stockholders’ equity at $43.3 million. Management expects this cash to fund operations into the second half of 2027.
For the three months ended June 30, 2026, collaboration revenue was $0.24 million, entirely from R&D services under the Dr. Reddy’s COYA 302 alliance. Operating expenses reached $7.3 million, driven by $5.0 million in research and development and $2.3 million in general and administrative costs. Net loss for the quarter was $6.6 million (or $0.28 per share), compared with $6.1 million a year earlier.
For the six‑month period, collaboration revenue totaled $0.49 million, while research and development and general and administrative expenses were $9.1 million and $6.0 million, respectively. Net loss for the six months was $13.8 million. The company added equity capital via a January 2026 private placement and put a $30.0 million at‑the‑market stock program in place. COYA 302, its lead ALS candidate, is in a Phase 2 trial and received FDA Fast Track Designation on May 11, 2026.
Coya Therapeutics, Inc. reported second quarter 2026 results and highlighted progress on its lead program COYA 302 for ALS and frontotemporal dementia. Enrollment in the Phase 2 ALSTARS ALS trial is proceeding as planned, with completion targeted in 2026 and topline data expected in the first quarter of 2027. The company also plans to initiate a Phase 2 study of COYA 302 in frontotemporal dementia in the second half of 2026.
Coya received FDA Fast Track Designation for COYA 302 in ALS and reported collaboration revenue of $243,745 for the quarter. Research and development expenses were $5.0 million, reflecting advancement of the COYA 302 ALS Phase 2 trial, while general and administrative expenses declined to $2.3 million. Net loss was $6.6 million. As of June 30, 2026, Coya held $43.2 million in cash and cash equivalents, which it states is sufficient to fund operations, as currently planned, past the ALSTARS topline readout and into the second half of 2027.
Coya Therapeutics, Inc. submitted an amendment to its March 29, 2026 current report that had announced the appointment of Mark H. Pavao to its Board of Directors, effective April 1, 2026. At that time, the Board had not yet determined any committee assignments for him.
The company now states that on August 6, 2026 its Board, acting on a recommendation from the Nominating and Corporate Governance Committee, appointed Mr. Pavao to the Audit Committee, effective immediately. Following this decision, the Audit Committee members are Dr. Dov Goldstein (Chair), Dr. Ann Lee, Dieter Weinand and Mark H. Pavao.
Coya Therapeutics, Inc. is the subject of an amended Schedule 13G filing by investment entities associated with Orin Hirschman, including AIGH Capital Management LLC and AIGH Investment Partners LLC. The reporting persons disclose beneficial ownership of 764,679 shares of common stock, representing 3.3% of the class, with sole voting and dispositive power over these shares and no shared power. The filing notes that this represents ownership of 5 percent or less of Coya’s outstanding common stock.
Coya Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 25, 2026. Stockholders elected two Class I directors to new three-year terms and ratified the company’s independent auditor for the 2026 fiscal year.
Secretary Wilbur Ross received 9,168,496 votes for and 2,818,233 withheld, with 4,585,732 broker non-votes. Dieter Weinand received 10,566,702 votes for and 1,420,027 withheld, with the same 4,585,732 broker non-votes. Stockholders also ratified Weaver and Tidwell, L.L.P. as the independent registered public accounting firm with 16,545,887 votes for, 22,661 against, and 3,913 abstentions.
Coya Therapeutics is asking stockholders to vote at a virtual annual meeting on June 25, 2026. Investors are being asked to elect two Class I directors, Wilbur Ross and Dieter Weinand, to serve until the 2029 meeting, and to ratify Weaver and Tidwell, L.L.P. as independent auditor for 2026.
The proxy details board structure, committee membership and independence, executive and director compensation, and the company’s 2021 equity incentive plan. It also outlines ownership levels, with 23,457,183 common shares outstanding as of May 1, 2026, and explains how stockholders can attend and vote electronically.
Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to sell shares of its common stock from time to time in "at the market" offerings for aggregate gross proceeds of up to $30,000,000.
The shares will be issued under an effective Form S-3 shelf registration statement and a prospectus supplement dated May 12, 2026. Leerink Partners will act as sales agent or, if separately agreed, as principal, and will receive a 3.0% commission on gross proceeds from any shares it sells.
Coya may suspend or terminate the program at any time, and the Sales Agreement will also end once all authorized shares are sold or if either party terminates it under the agreement’s terms.
Coya Therapeutics, Inc. has filed a prospectus supplement to offer up to $30,000,000 of common stock through a sales agreement with Leerink Partners under its existing $75,000,000 shelf registration. The shares may be sold from time to time as an at-the-market offering at prevailing market prices.
The prospectus supplement cites 23,457,183 shares outstanding as of May 1, 2026, notes a last reported sale price of $4.11 per share on May 8, 2026, and illustrates an example sale of 7,299,270 shares raising $30.0 million (before commissions). Leerink Partners will act as sales agent (or principal) and receive a 3.0% commission on gross proceeds. Net proceeds are intended for working capital and clinical development.